Myocardial Infarction Drugs: 2025 ACS Guideline, Reperfusion and Secondary Prevention

Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling.

Overview

Myocardial infarction (MI) is a time-critical manifestation of acute coronary syndrome (ACS). ST-elevation myocardial infarction (STEMI) and non-ST-elevation ACS require rapid ECG assessment, troponin testing and appropriate reperfusion/risk stratification. Pharmacotherapy complements—not replaces—urgent percutaneous coronary intervention (PCI) when indicated [1, 2].

Immediate treatments and mechanisms

  • Aspirin: irreversibly inhibits platelet COX-1 and thromboxane A2 production.
  • P2Y12 receptor antagonists: ticagrelor and prasugrel are often preferred to clopidogrel for ACS patients undergoing PCI when eligible; prasugrel is contraindicated with prior stroke/TIA. Ticagrelor is not a thienopyridine prodrug.
  • Anticoagulants: UFH, enoxaparin or other guideline-specific agents prevent thrombin generation during acute management and PCI; DOACs are not standard substitutes for acute procedural anticoagulation.
  • Nitrates: nitric oxide donors reduce ischemic symptoms but do not directly establish survival benefit; avoid in hypotension, suspected right ventricular infarction and after recent PDE5 inhibitors.
  • High-intensity statins: atorvastatin or rosuvastatin lower LDL and reduce subsequent cardiovascular events [1, 2].

Selecting reperfusion treatment

Primary percutaneous coronary intervention (PCI) is preferred for ST-elevation myocardial infarction (STEMI) when it can be delivered promptly. For an eligible patient presenting within 12 hours of symptom onset, fibrinolysis is indicated when the expected interval from first medical contact to PCI exceeds 120 minutes and contraindications have been excluded. Arrange transfer to a PCI-capable centre after fibrinolysis. Persistent ischaemia or failed reperfusion may require rescue PCI. Fibrinolysis has no routine role in non-ST-elevation ACS. [2]

2025 ACS antiplatelet recommendations

Default dual antiplatelet therapy (DAPT) is aspirin plus an oral P2Y12 inhibitor for at least 12 months in patients without high bleeding risk; duration and regimen may be modified according to PCI, need for oral anticoagulation, bleeding risk and clinical course. For selected patients on long-term anticoagulation after PCI, aspirin is generally stopped early while a P2Y12 drug is continued under specialist protocol. GI-risk patients may need a PPI [2].

Post-MI disease modification

High-intensity statins and lifestyle/cardiac rehabilitation are foundational. Beta blockers, ACE inhibitors/ARBs and mineralocorticoid receptor antagonists are particularly relevant with reduced LV function, heart failure or other indications; indefinite beta blockers should not be presumed necessary for every post-MI patient with preserved EF. Evaluate left-ventricular function and indications for other secondary-prevention therapies [1, 2].

Oxygen and haemodynamic assessment

Give supplemental oxygen for hypoxaemia. Routine oxygen at saturation of 90% or above has no demonstrated cardiovascular benefit. Nitrates can relieve ischaemic discomfort in haemodynamically suitable patients, but hypotension, suspected right ventricular infarction and recent phosphodiesterase-5 inhibitor use can make them unsafe. Persistent pain despite treatment calls for urgent reassessment of reperfusion. [2]

Assess for acute heart failure, low output, shock risk, bradycardia and conduction block before starting a beta blocker. An unstable patient may deteriorate if cardiac output depends on sympathetic drive. Reassess eligibility as the clinical picture changes. [2]

Major precautions

Morphine may delay absorption of oral P2Y12 inhibitors and can cause hypotension/respiratory depression; reserve for appropriate severe pain. Routine NSAIDs other than aspirin may increase cardiovascular/bleeding risk after MI. Monitor hemorrhage, kidney function, BP, heart rhythm and drug interactions. New chest pain warrants urgent assessment; do not rely on outpatient medications when MI is suspected [1, 2].

References

  1. Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
  2. Rao SV, O’Donoghue ML, Valgimigli M, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI guideline for management of patients with acute coronary syndromes. Circulation. 2025. doi:10.1161/CIR.0000000000001309. Available from: Full guideline.
Medical & AI Disclaimer

The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.

We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.

Leave a Reply

Your email address will not be published. Required fields are marked *